Shenzhen YHLO Biotech Co. Ltd. A

Yahuilong released its semi-annual report for 2026, achieving operating revenue of 888 million yuan, up 9.84% year-on-year; net profit attributable to shareholders of the listed company was 70.1308 million yuan, up 166.97% year-on-year. Among this, second-quarter net profit was 52 million yuan, and first-quarter net profit was 18 million yuan. Based on this calculation, second-quarter net profit increased 190% quarter-on-quarter.

Yahuilong released its 2026 half-year report, with first-half net profit attributable to the parent of 70.13 million yuan, up 166.97% year-on-year. The company's operating revenue was 888 million yuan, up 9.8% year-on-year; net profit attributable to the parent after deducting non-recurring items was 73.46 million yuan, up 46.8% year-on-year; net operating cash flow was 203 million yuan; earnings per share were 0.12 yuan. In the second quarter, the company's operating revenue was 490 million yuan, up 25.5% year-on-year; net profit attributable to the parent was 52.18 million yuan, up 223.7% year-on-year. As of the end of the second quarter, the company's total assets were 4.36 billion yuan, up 1.7% from the end of the previous year; net assets attributable to the parent were 2.752 billion yuan, up 2.02% from the end of the previous year. The company stated that no major risks occurred during the reporting period, business operations were stable, domestic market demand recovered, and international market demand continued to grow.

Yahuilong released its 2026 interim report, with a strong recovery in second-quarter performance, potentially confirming that the industry, after a collective decline in 2025 caused by medical insurance cost controls, may see a performance recovery inflection point in the second quarter of 2026. In the first half of the year, the company achieved operating revenue of 888 million yuan, up 9.84% year-on-year, net profit attributable to the parent of 70 million yuan, up 166.97% year-on-year, and non-GAAP net profit of 73 million yuan, up 46.81% year-on-year. Looking at the second quarter alone, operating revenue was 490 million yuan, up 25.47% year-on-year and up 23.21% quarter-on-quarter, of which domestic revenue was 412 million yuan, up 33.51% year-on-year and up 27.00% quarter-on-quarter. Self-produced product revenue was 424 million yuan, up 30.13% year-on-year and up 23.38% quarter-on-quarter, of which self-produced chemiluminescence business revenue was 371 million yuan, up 28.47% year-on-year and up 20.02% quarter-on-quarter. In addition, the National Healthcare Security Administration issued the Guidelines for Pricing of Laboratory Medical Service Items on August 14, which is favorable for autoimmune diagnostic demand. Yahuilong has a comprehensive solution for autoantibody testing across all methodologies and is expected to benefit. In the first half of the year, cardiovascular chemiluminescence reagent revenue grew 50.0% year-on-year, and the company said it expects to sustain high growth in the cardiovascular field.

Yahuilong announced on August 17 that the company recently received medical device registration certificates issued by the Guangdong Medical Products Administration for two microfluidic chemiluminescence testing instruments. The certified instruments are part of the company's research task as the lead unit for the national key research and development program under the 14th Five-Year Plan, specifically the key project on high-performance rapid on-site immunoassay system development within diagnostic and therapeutic equipment and biomedical materials. These certified instruments represent a phased achievement in the company's research and development of cutting-edge microfluidic biological detection technology, and are compatible with six microfluidic chemiluminescence testing reagents for which the company obtained certification in July 2026, helping to further enhance the company's core competitiveness. In the first quarter of 2026, Yahuilong achieved revenue of 398 million yuan and net profit attributable to the parent company of 17.95 million yuan.

Yahuilong announced that the company has received six medical device registration certificates for microfluidic chemiluminescence detection reagents from the Guangdong Medical Products Administration. These certificates are part of the key special project on diagnostic and therapeutic equipment and biomedical materials under the national key research and development program of the 14th Five-Year Plan, for which the company serves as the project lead. They mainly include high-sensitivity troponin I assay kit, N-terminal pro-B-type natriuretic peptide assay kit, creatine kinase isoenzyme assay kit, myoglobin assay kit, B-type natriuretic peptide assay kit, and D-dimer assay kit. The registration certificates are valid until 2031 and are primarily used for auxiliary diagnosis of diseases such as myocardial infarction and heart failure. In the first quarter of 2026, Yahuilong achieved revenue of 398 million yuan and net profit attributable to the parent company of 17.95 million yuan.